MDS Beacon -- Preliminary results of a Phase 2 trial show that the experimental drug panobinostat has little activity in patients with relapsed and resistant myelodysplastic syndromes.
MDS Beacon -- Preliminary results of a Phase 2 trial show that the experimental drug panobinostat has little activity in patients with relapsed and resistant myelodysplastic syndromes.